Rongsheng E. Wang obtained his Ph.D. in Bioorganic Chemistry in 2010 from the Department of Chemistry, Washington University in St. Louis (USA), where he worked with Professor John-Stephen Taylor to develop inhibitors of heat shock protein 70s for cancer therapy. From 2010 to 2012, he was a research scientist at Mediomics, LLC. From 2012 to 2016, he did a postdoc with Professor Peter G. Schultz at The Scripps Research Institute (CA, USA), where he developed novel therapeutic proteins, UAA-containing antibody drug conjugates for treatment of inflammatory diseases. Since 2016, he became a faculty member at Department of Chemistry, Temple University (USA). His current research interests lie in the identification of post-translational modification-related protein targets that are key to human diseases, and structure-based therapeutic design.